Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R M Mesters

Showing results (21-30 of 42) with videos related to

Pageof 5
Sort By:
Blood|February 7, 2001
Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myelomaB Dankbar, T Padró, R Leo, et al.
Blood|February 7, 2001
Increased angiogenesis in the bone marrow of patients with acute myeloid leukemiaT Padró, S Ruiz, R Bieker, et al.
Zeitschrift Fur Kardiologie|April 24, 2014
[Not Available]Andreas Hoffmeier, M Semik, Ch Schmid, et al.
Zeitschrift Fur Kardiologie|June 18, 2002
[Primary Burkitt lymphoma of the heart--diagnosis and therapy]A Hoffmeier, M Semik, Ch Schmid, et al.
Leukemia|June 29, 2007
Circulating angiopoietin-2 is a strong prognostic factor in acute myeloid leukemiaC Schliemann, R Bieker, N Thoennissen, et al.
Leukemia|March 3, 2007
Bevacizumab reduces VEGF expression in patients with relapsed and refractory acute myeloid leukemia without clinical antileukemic activityL Zahiragic, C Schliemann, R Bieker, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 6, 2008
Use of palifermin for the prevention of high-dose methotrexate-induced oral mucositisE Schmidt, N H Thoennissen, A Rudat, et al.
Critical Care Medicine|August 2, 2000
Prognostic value of protein C concentrations in neutropenic patients at high risk of severe septic complicationsR M Mesters, J Helterbrand, B G Utterback, et al.
Atherosclerosis|July 31, 1999
Overexpression of tissue-type plasminogen activator in atherosclerotic human coronary arteriesM B Steins, T Padró, C X Li, et al.
The European Respiratory Journal|February 14, 2009
Prognostic relevance of angiogenesis in stage III NSCLC receiving multimodality treatmentM Kreuter, M Kropff, A Fischaleck, et al.
Pageof 5

Showing results (21-30 of 42) with videos related to

Sort By:
Pageof 5
Blood|February 7, 2001
Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myelomaB Dankbar, T Padró, R Leo, et al.
Blood|February 7, 2001
Increased angiogenesis in the bone marrow of patients with acute myeloid leukemiaT Padró, S Ruiz, R Bieker, et al.
Zeitschrift Fur Kardiologie|April 24, 2014
[Not Available]Andreas Hoffmeier, M Semik, Ch Schmid, et al.
Zeitschrift Fur Kardiologie|June 18, 2002
[Primary Burkitt lymphoma of the heart--diagnosis and therapy]A Hoffmeier, M Semik, Ch Schmid, et al.
Leukemia|June 29, 2007
Circulating angiopoietin-2 is a strong prognostic factor in acute myeloid leukemiaC Schliemann, R Bieker, N Thoennissen, et al.
Leukemia|March 3, 2007
Bevacizumab reduces VEGF expression in patients with relapsed and refractory acute myeloid leukemia without clinical antileukemic activityL Zahiragic, C Schliemann, R Bieker, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 6, 2008
Use of palifermin for the prevention of high-dose methotrexate-induced oral mucositisE Schmidt, N H Thoennissen, A Rudat, et al.
Critical Care Medicine|August 2, 2000
Prognostic value of protein C concentrations in neutropenic patients at high risk of severe septic complicationsR M Mesters, J Helterbrand, B G Utterback, et al.
Atherosclerosis|July 31, 1999
Overexpression of tissue-type plasminogen activator in atherosclerotic human coronary arteriesM B Steins, T Padró, C X Li, et al.
The European Respiratory Journal|February 14, 2009
Prognostic relevance of angiogenesis in stage III NSCLC receiving multimodality treatmentM Kreuter, M Kropff, A Fischaleck, et al.
Pageof 5